Hyponatremia: Why it matters, how it presents, how we can manage it

Cleveland Clinic Journal of Medicine

Volumn 73, Issue SUPPL.3, 2006, Pages 4-12

  Douglas, Ivor ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEMECLOCYCLINE; DIURETIC AGENT; LITHIUM;

ACUTE DISEASE; ALGORITHM; CLASSIFICATION; HUMAN; HYPONATREMIA; REVIEW; RISK ASSESSMENT;

ACUTE DISEASE; ALGORITHMS; DEMECLOCYCLINE; DIURETICS; HUMANS; HYPONATREMIA; LITHIUM; RISK ASSESSMENT;

EID: 33750599391     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.Suppl_3.S4     Document Type: Article

References (28)

1. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 2003; 32:459-481.
2. Schrier R. The patient with hyponatremia or hypernatremia. In: Schrier RW, ed. Manual of Nephrology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:21-36.
3. Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001; 12(Suppl 17):S10-S14.
4. Han DS, Cho BS. Therapeutic approach to hyponatremia. Nephron 2002; 92(Suppl 1):9-13.
5. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985; 102:164-168.
6. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003; 337:169-172.
7. Vasa FR, Molitch ME. Endocrine problems in the chronically critically ill patient. Clin Chest Med 2001; 22:193-208.
8. Brenner GM. Syndrome of inappropriate antidiuretic hormone secretion. In: Brenner GM, ed. Brenner & Rector's The Kidney. 7th ed. New York, NY: Elsevier; 2004:897-903.
9. Al-Salman J, Kemp D, Randall D. Hyponatremia. West J Med 2002; 176:173-176.
10. Miller M. Hyponatremia: age-related risk factors and therapy decisions. Geriatrics 1998; 53:32-42.
11. Adrogué H, Madias N. Hyponatremia. N Engl J Med 2000; 342:1581-1589.
12. Schrier RW, ed. Atlas of Diseases of the Kidney. Philadelphia, PA: Current Medicine; 1999.
13. Fraser CL, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997; 102:67-77.
14. Nzerue CM, Baffoe-Bonnie H, You W, Falana B, Dai S. Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc 2003; 95:335-343.
15. Ayus JC, Arieff AI. Brain damage and postoperative hyponatremia: the role of gender. Neurology 1996; 46:323-328.
16. Medline Plus Medical Encyclopedia: Sodium-urine. U.S. National Library of Medicine and the National Institutes of Health. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/003599.htm. Accessed April 12, 2005.
17. Yatagai T, Kusaka I, Nakamura T, et al. Close association of severe hyponatremia with exaggerated release of arginine vasopressin in elderly subjects with secondary adrenal insufficiency. Eur J Endocrinol 2003; 148:221-226.
18. Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. Neurologist 2003; 9:290-300.
19. Craig S. Hyponatremia. eMedicine Web site. Updated January 20, 2005. Available at: http://www.emedicine.com/emerg/topic275.htm. Accessed April 13, 2005.
20. Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. J Natl Med Assoc 2004; 96:1305-1308.
21. Kim GH, Lee JW, Oh YK, et al. Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. J Am Soc Nephrol 2004; 15:2836-2843.
22. Chow KM, Szeto CC, Wong TY, Leung CB, Li PK. Risk factors for thiazide-induced hyponatraemia. QJM 2003; 96:911-917.
23. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4:1522-1530.
24. Lithium carbonate. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2004:1485-1486.
25. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002; 29:1-9.
26. Foster J. Syndrome of inappropriate antidiuretic hormone secretion. eMedicine Web site. Updated August 23, 2001. Available at: http://emedicine.com/emerg/topic784.htm. Accessed April 13, 2005.
27. Udelson J, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417-2423.
28. DeLuca GC, Nagy Z, Esiri MM, Davey P. Evidence for a role for apoptosis in central pontine myelinolysis. Acta Neuropathol (Berl) 2002; 103:590-598.